Cardio Diagnostics (CDIO) announces Atlas Healthcare coverage for Epi+Gen CHD and PrecisionCHD tests, expanding access to AI-powered coronary heart disease riskCardio Diagnostics (CDIO) announces Atlas Healthcare coverage for Epi+Gen CHD and PrecisionCHD tests, expanding access to AI-powered coronary heart disease risk

Cardio Diagnostics Expands Access to Precision Heart Disease Tests Through Atlas Healthcare Physicians

2026/06/24 21:45
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Cardio Diagnostics Holdings (NASDAQ: CDIO), a company specializing in AI-powered precision cardiovascular medicine, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations in Los Angeles and Orange counties, will cover the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. This move expands access to noninvasive blood tests designed to assess coronary heart disease risk and support personalized treatment planning.

The Epi+Gen CHD test evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are blood-based and do not require fasting or radiation exposure, making them easier to integrate into routine care. The partnership with Atlas Healthcare Physicians, which serves a diverse managed care population, is expected to broaden the adoption of precision cardiovascular medicine in community healthcare settings.

“This collaboration reflects our commitment to making advanced cardiovascular diagnostics more accessible to patients who need them,” said a spokesperson from Cardio Diagnostics. “By working with Atlas Healthcare Physicians, we can bring our precision tests to a larger population, potentially improving early detection and management of coronary heart disease.”

The announcement underscores the growing trend of integrating precision medicine into managed care networks. With cardiovascular disease remaining a leading cause of death in the U.S., tools that enable earlier and more accurate risk assessment are critical. The Epi+Gen CHD and PrecisionCHD tests offer a noninvasive alternative to traditional diagnostic methods, which often involve imaging or invasive procedures.

Cardio Diagnostics’ proprietary technology leverages an AI-driven Integrated Genetic-Epigenetic Engine to analyze blood samples. This approach aims to provide personalized insights into cardiovascular health, moving beyond one-size-fits-all risk factors. The company believes that such precision can lead to better outcomes and more efficient use of healthcare resources.

The coverage expansion comes as Cardio Diagnostics continues to build its commercial footprint. For more information about the company and its tests, visit their newsroom at https://nnw.fm/CDIO. The full press release is available at https://nnw.fm/EFQen.

As precision medicine gains traction, partnerships like this one between Cardio Diagnostics and Atlas Healthcare Physicians could pave the way for broader insurance coverage and patient access to advanced diagnostics. The implications extend beyond individual patient care, potentially reducing healthcare costs by preventing costly cardiovascular events through early intervention.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Cardio Diagnostics Expands Access to Precision Heart Disease Tests Through Atlas Healthcare Physicians.

The post Cardio Diagnostics Expands Access to Precision Heart Disease Tests Through Atlas Healthcare Physicians appeared first on citybuzz.

Market Opportunity
Humans.ai Logo
Humans.ai Price(HEART)
$0.0003453
$0.0003453$0.0003453
+0.75%
USD
Humans.ai (HEART) Live Price Chart

World Cup Combo: Aim for 200x

World Cup Combo: Aim for 200xWorld Cup Combo: Aim for 200x

Combine up to 20 World Cup matches in one order

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

CME Group to launch Solana and XRP futures options in October

CME Group to launch Solana and XRP futures options in October

The post CME Group to launch Solana and XRP futures options in October appeared on BitcoinEthereumNews.com. CME Group is preparing to launch options on SOL and XRP futures next month, giving traders new ways to manage exposure to the two assets.  The contracts are set to go live on October 13, pending regulatory approval, and will come in both standard and micro sizes with expiries offered daily, monthly and quarterly. The new listings mark a major step for CME, which first brought bitcoin futures to market in 2017 and added ether contracts in 2021. Solana and XRP futures have quickly gained traction since their debut earlier this year. CME says more than 540,000 Solana contracts (worth about $22.3 billion), and 370,000 XRP contracts (worth $16.2 billion), have already been traded. Both products hit record trading activity and open interest in August. Market makers including Cumberland and FalconX plan to support the new contracts, arguing that institutional investors want hedging tools beyond bitcoin and ether. CME’s move also highlights the growing demand for regulated ways to access a broader set of digital assets. The launch, which still needs the green light from regulators, follows the end of XRP’s years-long legal fight with the US Securities and Exchange Commission. A federal court ruling in 2023 found that institutional sales of XRP violated securities laws, but programmatic exchange sales did not. The case officially closed in August 2025 after Ripple agreed to pay a $125 million fine, removing one of the biggest uncertainties hanging over the token. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/cme-group-solana-xrp-futures
Share
BitcoinEthereumNews2025/09/17 23:55
Gold Slips Toward $4,000 as Persistent Inflation Data Bolsters Higher Rate Expectations

Gold Slips Toward $4,000 as Persistent Inflation Data Bolsters Higher Rate Expectations

BitcoinWorld Gold Slips Toward $4,000 as Persistent Inflation Data Bolsters Higher Rate Expectations Gold prices edged lower in early trading, approaching the
Share
bitcoinworld2026/06/30 07:50
MARA deploys military veterans to patrol MRSM hostels in bullying crackdown

MARA deploys military veterans to patrol MRSM hostels in bullying crackdown

KUALA LUMPUR, June 30 — A total of 16 Malaysian Armed Forces (ATM) veterans will report for duty as full-time ward...
Share
Malaymail2026/06/30 08:47